ter study included 13.356 patients Maraviroc Selzentry operated on for hip fracture and an additional 4.088 patients undergoing elective hip or knee replacement. Patients were randomized to receive aspirin or placebo on for 5 weeks, the dose is administered with RST fi before surgery. Other forms of prophylaxis were allowed, and heparin or low molecular weight heparin or low in 40% of the patients was used. Among 13.356 patients operated on for hip fractures, aspirin produced a 36% reduction in symptomatic DVT or pulmonary embolism. A Similar relative risk reduction of aspirin-treated patients who did or did not observe again U heparin or concomitant heparin with low molecular weight. These results are consistent with those of the meta-analysis performedSandercock and Associates 110 antiplatelet studies in patients with stroke. Compared with warfarin, heparin, low molecular weight heparins or danaparo Of, was recognized with aspirin Hnlichen rates or more DVT screening by ultrasound or venography, but the incidence of symptomatic events was associated low. 111 A big e randomized controlled Lee is necessary to determine the effectiveness of aspirin on coagulation inhibitors compared to the Pr Prevention of symptomatic VTE or life-threatening. Readers are requested to Falck et al ytterbium 112 in this guide for more information on the use of antiplatelet therapy for Pr Prevention of VTE. Placental insufficiency energy: Press eclampsia and fetal growth restriction are soup with Ood reduce placental blood ow, probably caused by a narrowing, thrombosis or both placental small arteries will be related . 113 Initial reports that the weak low-dose aspirin therapy reduces the risk of birth weight of newborns of severe low 114 and decreases caused the need for caesarean section in 114 mothers with high blood pressure due to pregnancy out-spread use of aspirin prophylaxis for the Press Prevention of Pr eclampsia. Subsequently End, several studies reported no beneficial effects than aspirin. 115 121 However, a systematic check of 59 studies of 37.560 women’s confidence that RMED is therapy with platelet aggregation inhibitors beneficial know that aspirin was a decrease of 17% risk for Pr Eclampsia, an 8% reduction in the risk of preterm birth, a 14% reduction in risk of fetal or neonatal death, and an associated 10% for gestational age babies smallfor. An individual analysis of 122 patients from 31 studies with a total of 32.217 patients, the meta U antiplatelet therapy for the primary again Re Pr Convention Of Pr Eclampsia showed a consistent benefit of aspirin for the Pr pets Investigated prevention of Pr Eclampsia in all sub-groups. 123 Aspirin in doses ranging from 50 to 150 mg / d accounted for 98% of the women included in this record. Readers are referred to Bates et al 124 in this guide for more information on the use of antithrombotic therapy w Offer during the pregnancy. Incidence and mortality t: There is compelling evidence from randomized controlled mortality trial sand EAA cancer. 125 126 A meta-analysis of eight studies, each patient monitored Strips, which have included 25.570 patients randomized showed that Clofarabine compared with no aspirin use, aspirin t Possible for a mean duration of treatment provided by a minimum of four years reduced the chances Todesf ll From cancer by 21%. Beneficiaries, the mortality rate does not appear to be related to aspirin.